Dear Ladies and Gentlemen,
I was 30 years old when I realized that something was wrong. As a medical doctor, I have worked at neurology department for more than four years. I received the first dose of Comirnaty (Pfizer/ Biontech) vaccine on 19 January and the second dose on ninth of February 2021.
In April, I first noticed a generalized malaise, moderate headache and taste disorders. Within 2 weeks, I developed a facial paralysis on the left side, discreet paralysis of the hypoglossal nerve on the right side and a massive ataxia of all extremities (Table
1).
Table 1
Development of neurological symptoms
April 2021 | 1. Generalized malaise and moderate headache |
April 2021 (2 days later) | 2. Taste disorders, facial paralysis on the left side |
May 2021 (1 week later) | 3. Progressive gait disturbance caused by a massive ataxia of all extremities |
May 2021 (a few days later) | 4. Paralysis of the hypoglossal nerve on the right side |
The MRI of the brain showed a weak FLAIR hyperintensity of the brainstem, mesencephalon and cerebellar around the fourth ventricle without contrast enhancement. MRI of cervical and thoracic spine were without pathological findings.
Lumbar puncture showed an inflammation of 10 cells/µl (normal range ≤ 5 cells/µl). Neurography and a second lumbar puncture later on were normal. CSF analysis revealed 2 cells/µl, normal protein (401 mg/l) and glucose (72 mg/dl). Bacterial culture and other tests including HSV, VZV, EBV, CMV, borreliosis and sarcoidosis were negative. Genetic testing for HLA-B-51 was negative. Strikingly, no positive antineuronal, paraneoplastic, or antiganglioside antibodies were present in serum or CSF. Oligoclonal bands were negative in both punctures, and there was no albumin cytologic dissociation. Full blood tests including ANA, ANCA, Syphilis, anti-MOG, Aquaporin-4 antibodies and the HIV test were negative.
After careful evaluation by neurologic experts, an autoimmune rhombencephalitis was diagnosed. As rhombencephalitis has been described to be associated with COVID-19 infection [
1‐
3], it was hypothesized that in my case, Comirnaty vaccination was the immunological trigger. This is the first report about an autoimmune rhombencephalitis after Comirnaty vaccination whereas e.g. Guillian-Barré syndrome, which is pathophysiological related, was described quite often after that vaccine [
4].
A high dose intravenous cortisone therapy with 1000 mg methylprednisolone per day for a total of 5 days was initiated. Thereafter, oral corticosteroids were tapered within two weeks starting with 80 mg prednisolone per day.
As a result, the neurological symptoms, especially the ataxia, rapidly decreased. I was referred to an acute rehabilitation facility where most symptoms improved significantly within a few weeks.
Why did I write this article? What do we learn from it?
Firstly, I think it is an interesting and rare, atypical case of rhombencephalitis. I have learned a lot about the very low prevalence of my disease, the (unclear) prognosis, the treatment options, the possible complications, and the possible connection with COVID-19 vaccination. Even though the time between vaccination and the appearance of symptoms seems to be rather long, we did not find any other trigger for this orphan disease.
Secondly, it showed me how quickly one can fall ill and that there is no guarantee of health.
Thirdly, it was very difficult for me as a neurologist to recognize specific neurological symptoms in myself. It makes a great difference if you examine a patient or if you are the patient. It makes me compliant, cautious, and grateful.
Finally, as a scientist, it has shown me that we do not yet fully understand the pathophysiological characteristics of encephalitis associated with SARS-CoV-2.
Increasing evidence suggests that there is a wide range of complications of SARS-CoV-2 infection, including neurological disorders [
5]. Guillain-Barré syndrome, Bickerstaff-Encephalitis, Miller Fisher syndrome, acute necrotizing encephalitis, myelitis, acute disseminated encephalomyelitis (ADEM), and myasthenia gravis have been reported after COVID-19 [
1,
6‐
9]. All reviewed studies demonstrate that neurological manifestations are broad and heterogeneous suggesting different underlying pathogenic processes and pathways [
10].
The possible relationship between the COVID-19 infection and these neuroinflammatory diseases would be consistent with a post-infectious immune-mediated mechanism. It is imaginable, that this may also occur after a vaccination.
In literature, we also found some cases with an encephalitis related to a H1N1 vaccination [
11], which support our hypothesis.
In addition to that, smell and taste disorders are common with COVID-19. They appear especially in previously healthy, young people [
12]. In my case, I also had taste disorders as an early symptom. This could be a supplementary hint for a similar pathophysiological origin (Additional file
1).
Furthermore, we did not find any other causes for this type of encephalitis. We could eliminate other infectious, autoimmune, paraneoplastic and genetic causes by blood testing and MRI imaging.
In conclusion we do not yet know much about complications after vaccination [
13]. Currently, there is not much data available [
4]. In rare cases, vaccination may cause an immunological reaction and delayed inflammation, the consequences of which we have not yet deciphered. An autoimmune rhombencephalitis may be considered as a rare potential mRNA-associated vaccination side effect [
1,
3].
Follow-up studies will be necessary to ascertain the long-term neurological consequences of COVID-19 vaccines.
Description of the MRI findings
The MRI of the brain shows an axial FLAIR on the right side with a weak hyperintensity cerebellar around the fourth ventricle. On the left side is a sagittal T2 weighted image, which illustrates a bright abnormality of the rhombencephalon. The conspicuous features are marked with a red arrow.
Acknowledgements
I am deeply grateful for the very motivating rehabilitation team and the permanent support of my family, especially of my wife.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.